Klaria Pharma Holding AB
Klaria Pharma Holding AB (publ.), a pharmaceutical company develops and commercializes medication for migraine and cancer related pain, and opioid overdose and anaphylactic shock. Its product pipeline includes Sumatriptan, a novel the treatment of migraine which is in final stage of approval; Epinephrine/Adrenaline which is in Phase I clinical trial for the treatment of acute allergic reaction; a… Read more
Klaria Pharma Holding AB (KLAR) - Net Assets
Latest net assets as of December 2025: Skr-3.88 Million SEK
Based on the latest financial reports, Klaria Pharma Holding AB (KLAR) has net assets worth Skr-3.88 Million SEK as of December 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr40.77 Million) and total liabilities (Skr44.65 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr-3.88 Million |
| % of Total Assets | -9.51% |
| Annual Growth Rate | N/A |
| 5-Year Change | -105.59% |
| 10-Year Change | -102.42% |
| Growth Volatility | 67.12 |
Klaria Pharma Holding AB - Net Assets Trend (2014–2025)
This chart illustrates how Klaria Pharma Holding AB's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Klaria Pharma Holding AB (2014–2025)
The table below shows the annual net assets of Klaria Pharma Holding AB from 2014 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | Skr-3.88 Million | -217.37% |
| 2024-12-31 | Skr3.31 Million | -91.97% |
| 2023-12-31 | Skr41.13 Million | -45.93% |
| 2022-12-31 | Skr76.08 Million | +9.60% |
| 2021-12-31 | Skr69.42 Million | -36.66% |
| 2020-12-31 | Skr109.59 Million | +33.47% |
| 2019-12-31 | Skr82.11 Million | -13.29% |
| 2018-12-31 | Skr94.70 Million | -38.31% |
| 2017-12-31 | Skr153.52 Million | -4.07% |
| 2016-12-31 | Skr160.04 Million | -8.33% |
| 2015-12-31 | Skr174.59 Million | +38666.67% |
| 2014-12-31 | Skr-452.69K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Klaria Pharma Holding AB's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 3888700000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr4.10 Million | % |
| Other Comprehensive Income | Skr-210.00K | % |
| Other Components | Skr31.12 Million | % |
| Total Equity | Skr-3.88 Million | 100.00% |
Klaria Pharma Holding AB Competitors by Market Cap
The table below lists competitors of Klaria Pharma Holding AB ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
VARIOUS EATERIES LS -01
F:63U
|
$15.08 Million |
|
Laser Photonics Corporation Common Stock
NASDAQ:LASE
|
$15.09 Million |
|
Essar Shipping Limited
NSE:ESSARSHPNG
|
$15.09 Million |
|
SAN-EL Muhendislik Elektrik Taahhut Sanayi ve Ticaret AS
IS:SANEL
|
$15.09 Million |
|
DIGITAL WORKFORCE SRV.EO1
F:DQ4
|
$15.07 Million |
|
PREDATOR OIL A.GAS HLDGS
F:1EM
|
$15.06 Million |
|
Il Sung Const
KO:013360
|
$15.05 Million |
|
Wentel Engineering Holdings Berhad
KLSE:0298
|
$15.04 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Klaria Pharma Holding AB's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 3,307,000 to -3,881,000, a change of -7,188,000 (-217.4%).
- Net loss of 38,900,000 reduced equity.
- New share issuances of 31,795,000 increased equity.
- Other comprehensive income decreased equity by 87,000.
- Other factors increased equity by 4,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-38.90 Million | -1002.32% |
| Share Issuances | Skr31.80 Million | +819.25% |
| Other Comprehensive Income | Skr-87.00K | -2.24% |
| Other Changes | Skr4.00K | +0.1% |
| Total Change | Skr- | -217.36% |
Book Value vs Market Value Analysis
This analysis compares Klaria Pharma Holding AB's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2014-12-31 | Skr1.00 | Skr0.80 | x |
| 2015-12-31 | Skr8.36 | Skr0.80 | x |
| 2016-12-31 | Skr5.00 | Skr0.80 | x |
| 2017-12-31 | Skr4.72 | Skr0.80 | x |
| 2018-12-31 | Skr2.88 | Skr0.80 | x |
| 2019-12-31 | Skr2.64 | Skr0.80 | x |
| 2020-12-31 | Skr2.37 | Skr0.80 | x |
| 2021-12-31 | Skr1.26 | Skr0.80 | x |
| 2022-12-31 | Skr1.31 | Skr0.80 | x |
| 2023-12-31 | Skr0.41 | Skr0.80 | x |
| 2024-12-31 | Skr0.03 | Skr0.80 | x |
| 2025-12-31 | Skr-0.02 | Skr0.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Klaria Pharma Holding AB utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -432.22%
- • Asset Turnover: 0.22x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-165.58%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2015 | -3.20% | 0.00% | 0.00x | 1.01x | Skr-23.05 Million |
| 2016 | -9.09% | 0.00% | 0.00x | 1.01x | Skr-30.55 Million |
| 2017 | -14.05% | -948.04% | 0.01x | 1.02x | Skr-36.92 Million |
| 2018 | -28.83% | -4207.40% | 0.01x | 1.12x | Skr-36.78 Million |
| 2019 | -27.39% | -532.61% | 0.04x | 1.24x | Skr-30.70 Million |
| 2020 | -46.94% | -712.45% | 0.05x | 1.21x | Skr-62.40 Million |
| 2021 | -77.12% | -875.88% | 0.05x | 1.70x | Skr-60.48 Million |
| 2022 | -83.83% | -1086.81% | 0.05x | 1.58x | Skr-71.38 Million |
| 2023 | -87.00% | -423.28% | 0.12x | 1.77x | Skr-39.90 Million |
| 2024 | -1443.91% | -2124.11% | 0.04x | 17.32x | Skr-48.08 Million |
| 2025 | 0.00% | -432.22% | 0.22x | 0.00x | Skr-38.51 Million |
Industry Comparison
This section compares Klaria Pharma Holding AB's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $105,520,346
- Average return on equity (ROE) among peers: -63.03%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Klaria Pharma Holding AB (KLAR) | Skr-3.88 Million | -3.20% | N/A | $15.08 Million |
| BioGaia AB (publ) (BIOG-B) | $230.35 Million | 33.15% | 0.21x | $714.80 Million |
| Dicot AB (DICOT) | $73.40 Million | -109.26% | 0.16x | $55.17 Million |
| Enzymatica publ AB (ENZY) | $76.61 Million | -64.91% | 0.64x | $20.94 Million |
| Enorama Pharma AB (ERMA) | $17.02 Million | -96.01% | 1.28x | $566.46K |
| Gabather AB (publ) (GABA) | $10.96 Million | -155.04% | 0.40x | $732.74K |
| Moberg Pharma AB (publ) (MOB) | $76.79 Million | -8.31% | 0.20x | $38.42 Million |
| Nanexa AB (NANEXA) | $101.53 Million | -11.22% | 0.36x | $39.92 Million |
| Newbury Pharmaceuticals AB (NEWBRY) | $51.92 Million | -29.67% | 0.75x | $559.69K |
| Orexo AB (ORX) | $311.10 Million | -126.01% | 0.76x | $45.88 Million |